This led to the Nordic phase III trial (NOA-9) in newly diagnosed, m-MGMT GBM which randomized 141 patients to standard therapy (RT-TMZ followed by adjuvant TMZ) or experimental therapy with radiation alone followed by lomustine and TMZ every 6 weeks [4]. The gene discussed is MGMT; the disease is glioblastoma.